P
49.33
-0.46 (-0.92%)
| Penutupan Terdahulu | 49.79 |
| Buka | 49.82 |
| Jumlah Dagangan | 818,695 |
| Purata Dagangan (3B) | 1,169,604 |
| Modal Pasaran | 3,918,681,344 |
| Harga / Pendapatan (P/E TTM) | 7.00 |
| Harga / Jualan (P/S) | 2.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 33.56% |
| Margin Operasi (TTM) | 82.43% |
| EPS Cair (TTM) | 6.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 459.70% |
| Nisbah Semasa (MRQ) | 3.89 |
| Aliran Tunai Operasi (OCF TTM) | 691.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 526.00 M |
| Pulangan Atas Aset (ROA TTM) | 24.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | PTC Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.4
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.40 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.40% |
| % Dimiliki oleh Institusi | 101.06% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 118.00 (Cantor Fitzgerald, 139.21%) | Beli |
| Median | 73.00 (47.98%) | |
| Rendah | 46.00 (Barclays, -6.75%) | Pegang |
| Purata | 73.67 (49.34%) | |
| Jumlah | 7 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 48.85 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 03 Sep 2025 | 118.00 (139.21%) | Beli | 55.55 |
| 29 Jul 2025 | 120.00 (143.26%) | Beli | 49.29 | |
| B of A Securities | 20 Aug 2025 | 76.00 (54.06%) | Beli | 48.85 |
| 29 Jul 2025 | 84.00 (70.28%) | Beli | 49.29 | |
| Morgan Stanley | 20 Aug 2025 | 71.00 (43.93%) | Beli | 48.85 |
| Wells Fargo | 20 Aug 2025 | 73.00 (47.98%) | Beli | 48.85 |
| 08 Aug 2025 | 79.00 (60.15%) | Beli | 45.38 | |
| RBC Capital | 08 Aug 2025 | 63.00 (27.71%) | Beli | 45.38 |
| Barclays | 29 Jul 2025 | 46.00 (-6.75%) | Pegang | 49.29 |
| Truist Securities | 29 Jul 2025 | 86.00 (74.34%) | Beli | 49.29 |
| 17 Jun 2025 | 80.00 (62.17%) | Beli | 50.85 | |
| UBS | 29 Jul 2025 | 80.00 (62.17%) | Beli | 49.29 |
| Citigroup | 28 Jul 2025 | 50.00 (1.36%) | Pegang | 44.34 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JACOBSON ALLAN STEVEN | - | 49.79 | -1,667 | -83,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,667 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -83,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 49.79 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| JACOBSON ALLAN STEVEN | Pengarah | 28 Aug 2025 | Jual (-) | 1,667 | 49.79 | 83,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Aug 2025 | Pengumuman | PTC Therapeutics to Participate at Upcoming Investor Conferences |
| 19 Aug 2025 | Pengumuman | PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA |
| 07 Aug 2025 | Pengumuman | PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results |
| 28 Jul 2025 | Pengumuman | PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) |
| 21 Jul 2025 | Pengumuman | PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results |
| 23 Jun 2025 | Pengumuman | Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) |
| 19 Jun 2025 | Pengumuman | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |